Pharmaceutical Technology
DECEMBER 24, 2023
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Metastatic Biliary Tract Cancer.
Drug Patent Watch
DECEMBER 24, 2023
Annual Drug Patent Expirations for ABILIFY Abilify is a drug marketed by Otsuka and Otsuka Pharm Co Ltd and is included in seven NDAs. It is available from one supplier.… The post New patent expiration for Otsuka drug ABILIFY appeared first on DrugPatentWatch - Make Better Decisions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
DECEMBER 24, 2023
(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Triple-Negative Breast Cancer (TNBC).
Drug Patent Watch
DECEMBER 24, 2023
Annual Drug Patent Expirations for ABILIFY+MYCITE+KIT Abilify Mycite Kit is a drug marketed by Otsuka and is included in one NDA. It is available from one supplier. There are twenty-nine… The post New patent expiration for Otsuka drug ABILIFY MYCITE KIT appeared first on DrugPatentWatch - Make Better Decisions.
Pharmaceutical Technology
DECEMBER 24, 2023
(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Metastatic Colorectal Cancer.
Drug Patent Watch
DECEMBER 24, 2023
This chart shows the pharmaceutical companies with the most lotion dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most lotion dosed drugs… The post Which pharmaceutical companies have the most lotion dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
DECEMBER 24, 2023
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Metastatic Biliary Tract Cancer.
Pharmaceutical Technology
DECEMBER 24, 2023
Mecbotamab vedotin is under clinical development by BioAtla and currently in Phase II for Breast Cancer.
Expert insights. Personalized for you.
130 
Let's personalize your content